Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021
Jul 28, 2021Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Jul 28, 2021Clin Cancer Res 2021
Venet David, Gomez Henry, Semiglazov Vladimir, de Azambuja Evandro, Huober Jens, Nuciforo Paolo, Di Cosimo Serena, Piccart-Gebhart Martine, Loi Sherene, Rothé Françoise, Saura Cristina, Wang Yingbo, Rediti Mattia, Maetens Marion, Fumagalli Debora, Brown David N, Majjaj Samira, Salgado Roberto, Pusztai Lajos, Harbeck Nadia, El-Abed Sarra, Sotiriou Christos
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübbe K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22:1151-1161.
Jul 9, 2021Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Jul 9, 2021Lancet Oncol 2021; 22:1151-1161
Denkert Carsten, Huober Jens, Rhiem Kerstin, Marme Frederik, Reimer Toralf, Schmidt Marcus, Sinn Bruno V, Janni Wolfgang, Stickeler Elmar, Michel Laura, Stötzer Oliver, Hahnen Eric, Furlanetto Jenny, Seiler Sabine, Nekljudova Valentina, Untch Michael, Solbach Christine, Lübbe Kristina, Seither Fenja, Schneeweiss Andreas, Link Theresa, Blohmer Jens-Uwe, Just Marianne, Wimberger Pauline, Forberger Almuth, Tesch Hans, Jackisch Christian, Schmatloch Sabine, Reinisch Mattea, Solomayer Erich F, Schmitt Wolfgang D, Hanusch Claus, Fasching Peter A, Loibl Sibylle
Response to comment on: Research projects in human genetics in Switzerland: analysis of research protocols submitted to Cantonal Ethics Commissions in 2018.
Driessen S, Gervasoni P. Response to comment on: Research projects in human genetics in Switzerland: analysis of research protocols submitted to Cantonal Ethics Commissions in 2018. Swiss Med Wkly 2021; 151:w20518.
Jul 7, 2021Response to comment on: Research projects in human genetics in Switzerland: analysis of research protocols submitted to Cantonal Ethics Commissions in 2018.
Jul 7, 2021Swiss Med Wkly 2021; 151:w20518
Driessen Susanne, Gervasoni Pietro
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein H, Gnant M, Winer E, Senn H, Regan M, Poortmans P, Weber W, Thürlimann B, Curigliano G, Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32:1216-1235.
Jul 6, 2021Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Jul 6, 2021Ann Oncol 2021; 32:1216-1235
Burstein H J, Gnant M, Winer E P, Senn H J, Regan M M, Poortmans P, Weber W P, Thürlimann Beat, Curigliano G, Panelists of the St Gallen Consensus Conference
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 153:203-212.
Jun 26, 2021Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Jun 26, 2021Eur J Cancer 2021; 153:203-212
Marme Frederik, Loibl Sibylle, Lederer Bianca, Tesch Hans, Hanusch Claus, Denkert Carsten, Rey Julia, Rhiem Kerstin, Link Theresa, Nekljudova Valentina, Jackisch Christian, Fasching Peter A, Huober Jens, Blohmer Jens-Uwe, Schneeweiss Andreas, Michel Laura, Solbach Christine, Untch Michael
BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients
Wischnewsky M, Wöckel A, Kreienberg R, Janni W, Wolters R, Blettner M, Müller-Reiter M, Kiesel M, Bekes I, Salmen J, Davut D, Joukhadar R, De Gregorio A, Diessner J, Schwentner L, Ebner F. BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients. Cancers (Basel) 2021; 13
Jun 22, 2021BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients
Jun 22, 2021Cancers (Basel) 2021; 13
Wischnewsky Manfred, Wöckel Achim, Kreienberg Rolf, Janni Wolfgang, Wolters Regine, Blettner Maria, Müller-Reiter Max, Kiesel Matthias, Bekes Inga, Salmen Jessica, Davut Dayan, Joukhadar Ralf, De Gregorio Amelie, Diessner Joachim Diessner, Schwentner Lukas, Ebner Florian
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
Johnston S, Hardebeck M, Martin H, Andre V, Sohn J, Toi M, Huober J, Martín M, O'Shaughnessy J, Goetz M. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer 2021; 7:80.
Jun 22, 2021Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
Jun 22, 2021NPJ Breast Cancer 2021; 7:80
Johnston Stephen, Hardebeck Molly C, Martin Holly R, Andre Valerie A M, Sohn Joohyuk, Toi Masakazu, Huober Jens, Martín Miguel, O'Shaughnessy Joyce, Goetz Matthew P
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
Thill M, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Jackisch C, Friedrich M, Kolberg-Liedtke C, Fallenberg E, Fasching P, Fehm T, Kümmel S, Kühn T, Krug D, Kreipe H, Huober J, Heil J, Harbeck N, Gluz O, Gerber B, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:214-227.
Jun 1, 2021AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
Jun 1, 2021Breast Care (Basel) 2021; 16:214-227
Thill Marc, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Maass Nicolai, Lux Michael P, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Janni Wolfgang, Müller Volkmar, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Luftner Diana, Loibl Sibylle, Dall Peter, Budach Wilfried, Blohmer Jens-Uwe, Bauerfeind Ingo, Banys-Paluchowski Maggie, Albert Ute-Susann, Jackisch Christian, Friedrich Michael, Kolberg-Liedtke Cornelia, Fallenberg Eva M, Fasching Peter A, Fehm Tanja, Kümmel Sherko, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Gluz Oleg, Gerber Bernd, Ditsch Nina
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
Ditsch N, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Fallenberg E, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Kolberg-Liedtke C, Friedrich M, Fasching P, Fehm T, Gerber B, Kümmel S, Kühn T, Krug D, Kreipe H, Jackisch C, Huober J, Heil J, Harbeck N, Gluz O, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:228-235.
May 27, 2021AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
May 27, 2021Breast Care (Basel) 2021; 16:228-235
Ditsch Nina, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Maass Nicolai, Lux Michael P, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Janni Wolfgang, Müller Volkmar, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Luftner Diana, Loibl Sibylle, Fallenberg Eva M, Dall Peter, Budach Wilfried, Blohmer Jens-Uwe, Bauerfeind Ingo, Banys-Paluchowski Maggie, Albert Ute-Susann, Kolberg-Liedtke Cornelia, Friedrich Michael, Fasching Peter A, Fehm Tanja, Gerber Bernd, Kümmel Sherko, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Jackisch Christian, Huober Jens, Heil Jörg, Harbeck Nadia, Gluz Oleg, Thill Marc
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
Untch M, Harbeck N, Thill M, Schneeweiss A, Müller V, Luftner D, Loibl S, Kühn T, Krug D, Kolberg-Liedtke C, Janni W, Jackisch C, Huober J, Haidinger R, Denkert C, Budach W, Brucker S, Fasching P, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd 2021; 81:637-653.
May 19, 2021Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
May 19, 2021Geburtshilfe Frauenheilkd 2021; 81:637-653
Untch Michael, Harbeck Nadia, Thill Marc, Schneeweiss Andreas, Müller Volkmar, Luftner Diana, Loibl Sibylle, Kühn Thorsten, Krug David, Kolberg-Liedtke Cornelia, Janni Wolfgang, Jackisch Christian, Huober Jens, Haidinger Renate, Denkert Carsten, Budach Wilfried, Brucker Sara Y, Fasching Peter A, Thomssen Christoph
Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences
Schulz S, Steinacker J, Leinert E, Huober J, Janni W, Treff G, Kirsten J, Otto S, Schumann U, Bizjak D. Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences. Disabil Rehabil 2021:1-8.
May 11, 2021Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences
May 11, 2021Disabil Rehabil 2021:1-8
Schulz Sebastian V W, Steinacker Jürgen M, Leinert Elena, Huober Jens, Janni Wolfgang, Treff Gunnar, Kirsten Johannes, Otto Stephanie, Schumann Uwe, Bizjak Daniel A
In Reply
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. In Reply. Oncologist 2021; 26:e1286-e1287.
Apr 19, 2021In Reply
Apr 19, 2021Oncologist 2021; 26:e1286-e1287
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Freiberger S, Brada M, Fritz C, Höller S, Vogetseder A, Horcic M, Bihl M, Michal M, Lanzer M, Wartenberg M, Borner U, Bode P, Broglie M, Rordorf T, Morand G, Rupp N. SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 2021; 23:473-487.
Apr 18, 2021SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Apr 18, 2021Neoplasia 2021; 23:473-487
Freiberger Sandra N, Brada Muriel, Fritz Christine, Höller Sylvia, Vogetseder Alexander, Horcic Milo, Bihl Michel, Michal Michal, Lanzer Martin, Wartenberg Martin, Borner Urs, Bode Peter K, Broglie Martina A, Rordorf Tamara, Morand Grégoire B, Rupp Niels J
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:603-608.
Apr 1, 2021Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Apr 1, 2021JAMA Oncol 2021; 7:603-608
Filho Otto Metzger, Rugo Hope S, Huober Jens, Golshan Mehra, Sikov William M, von Minckwitz Gunter, Rastogi Priya, Maag David, Wolmark Norman, Denkert Carsten, Untch Michael, O'Shaughnessy Joyce, Stover Daniel G, Asad Sarah, Ansell Peter J, Watson Mark, Loibl Sibylle, Geyer Charles E, Bae Junu, Collier Katharine, Cherian Mathew, Symmans W Fraser
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Chic N, Prat A, Huober J, Saura C, Di Cosimo S, Láng I, de Azambuja E, Wang Y, Hilbers F, Fumagalli D, Salgado R, Nuciforo P, Luen S, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2021
Mar 31, 2021Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Mar 31, 2021J Natl Cancer Inst 2021
Chic Nuria, Prat Aleix, Huober Jens, Saura Cristina, Di Cosimo Serena, Láng István, de Azambuja Evandro, Wang Yingbo, Hilbers Florentine, Fumagalli Debora, Salgado Roberto, Nuciforo Paolo, Luen Stephen J, Loi Sherene
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
Mar 18, 2021Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Mar 18, 2021Eur J Cancer 2021; 148:159-170
Villegas Sonia L, Huober Jens, Lederer Bianca, van Mackelenbergh Marion, Tesch Hans, Jackisch Christian, Rezai Mahdi, Sinn Peter, Sinn Bruno V, Hackmann John, Kiechle Marion, Schneeweiss Andreas, Weichert Wilko, Denkert Carsten, Schmitt Wolfgang D, Hanusch Claus, Nekljudova Valentina, Pfarr Nicole, Engel Jutta, Untch Michael, Schrodi Simone, Holms Frank, Ulmer Hans U, Fasching Peter A, Weber Karsten E, Albig Christian, Heinrichs Clemens, Marme Frederik, Hartmann Arndt, Loibl Sibylle
Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC cancer 2021; 21:229.
Mar 6, 2021Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
Mar 6, 2021BMC cancer 2021; 21:229
Herrmann Christian, Morant Rudolf, Walser Esther, Mousavi Mohsen, Thürlimann Beat
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly 2021; 151:w20464.
Mar 1, 2021Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Mar 1, 2021Swiss Med Wkly 2021; 151:w20464
Stoffel Sandro Tiziano, Lupatsch Judith E, Schwenkglenks Matthias, Dietrich Daniel, Schär Corinne, Feller Anita, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Gillessen Silke, Cathomas Richard, Thürlimann Beat, von Moos Roger, Mark Michael Thomas
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26:e522.
Mar 1, 2021Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Mar 1, 2021Oncologist 2021; 26:e522
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). BMC cancer 2021; 21:182.
Feb 19, 2021Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Feb 19, 2021BMC cancer 2021; 21:182
Ribi Karin, von Moos Roger, Caspar Clemens B, Mannhart Meinrad, von Burg Philippe, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Thürlimann Beat, Mark Michael